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Abstract 
Current CoVID-19 pandemic is spreading rapidly worldwide, and it may become one of 
the largest pandemic events in modern history if out of control.  It appears most of the SARS-CoV-
2 virus infection resulted deaths are mainly due to dysfunctions or failures of the lung or multiple 
organs that could be attributed to host’s immunodysfunctions particularly hyperinflammatory type 
disorders.  In this brief review and study, a math model is proposed to correlate the Pathogen 
Infection Recovery Probability (PIRP) versus Proinflammatory Anti-Pathogen Species (PIAPS) 
levels within a host unit, where a maximum PIRP is exhibited when the PIAPS levels are equal to 
or around PIAPS equilibrium levels at the pathogen elimination or clearance onset.  Based on this 
model, rational or effective therapeutic strategies at right stages or timing, with right type of agents 
(immuno-stimulators or immuno-suppressors), and right dosages, may be designed and 
implemented that are expected to effectively achieve maximum PIRP or reduce the mortality.   
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Current COVID-19 pandemic due to SARS-CoV-2 viruses have already spread around the 
globe and have resulted in over thirty thousand human deaths with twenty times more confirmed 
infections [1-2].  In addition to loss of human life, social and economic losses or effects could be 
significant.  A number of earlier global pandemics occurred in human history can be attributed to 
pathogen infections [3].  Though there are differences among different pathogen induced 
infections, there were certain similarities among all pathogen infections.  The pathogens here 
mainly refer to biological microorganisms such as viruses (including the new SARS-CoV-2 virus) 
and bacteria that can self-replicate in a biological host and can trigger or initiate a host immune 
system responses resulting in the production (clonal expansion) of anti-pathogen species (APS), 
including a series of proinflammatory anti-pathogen species (PIAPS).  PIAPS here mainly refer to 
“double-edged sword” species such as certain white blood cells (WBCs) or their generated/related 
species, such as oxidative radical species and antibodies [4-6], cytokines [7-12, 18-20], etc.  
“Double-edged sword” refers to certain PIAPS that not only attack the pathogens but also attack 
host normal cells and tissues [4-12, 18-20].   
Pathogen infection modeling could be very useful for understanding the infection 
mechanisms and processes, and for preventive or therapeutic strategies.  However, most of the 
existing modeling works are mainly focusing on multiple host infection and transmittance statistics 
over time domain [13-17], very few modeling work provide insights on pathogen infection 
recovery probability (PIRP) over anti-pathogens species (APS), particularly over proinflammatory 
anti-pathogen species (PIAPS) that is the focus of this study.   
A pathogen infection in a host may result in pathogen un-controlled growth if the host 
immune system is too weak, deficient, or dysregulated (including immunoparalysis and a serious 
immune deficiency syndromes) that could result in sepsis or septic shocks [20].  In a host with 
normal immune response system, as illustrated in Figure 1, the pathogen infection at time t0 (end 
of incubation period) typically trigger a normal and efficient growth (clonal expansion) of immune 
system generated anti-pathogen species (APS at an initial level x0) and ideally shall result in 
pathogen being eliminated/cleared at te [13].  Once the pathogen is eliminated by the APS at te, the 
APS (including PIAPS) growth are expected to cease and remain at their equilibrium levels xe.  
Certain APS (such as certain pathogen specific antibodies) are expected to remain at their 
equilibrium levels for certain period of time so the same pathogen infection can be prevented or 
inhibited (principle of vaccination), though antibody equilibrium level slow decay in long period 
of time are normal or expected [13-17].   
 
  
Pre-print/(DOI:10.21203/rs.3.rs-17318/v1)/(033120/v5)  
 3 
 
 
Figure 1.  Schematic levels of pathogen (short dashed red curve) and host immune system 
generated anti-pathogen species (APS), including proinflammatory anti-pathogen species 
(PIAPS), for normal (solid blue curve) and abnormal (long dashed blue line, reflecting 
hyperinflammatory disorder) immune response reactions over time.  
However, in certain immunodysfunction disorders, particularly certain hyperinflammatory 
disorders, such as cytokine release syndromes (CRS) or cytokine storm (CS) [4-12], macrophage 
activation syndromes (MAS) or macrophage-cytokine self-amplifying loop (MCSAL) [11], WBS 
proliferative disorders [4], certain PIAPS can grow out of control or not being efficiently 
dampened by the host anti-inflammatory species (e.g., IL-10) even after te where the pathogen may 
have been eliminated.  It has been known that a number of PIAPS attack or damage normal or 
healthy cells resulting in tissue death (gangrene) and multiple organ dysfunctions or failures [2, 4-
12, 18-20].  For this reason and for potential and practical therapeutic strategies, a Gaussian bell 
shaped normal distribution function Y is proposed here to model the Pathogen Infection Recovery 
Probability (PIRP, or the survivability, counter to the mortality) versus the PIAPS levels x (shown 
in Figure 2) and is exhibited with equation (1):   
𝒀 = 𝜷 𝒆𝒙𝒑[-(x-xe)2/α]   (1) 
where α parameter is proportional to the PIRP distribution peak full width at half maximum 
(FWHM) that affects the PIAPS level range width around PIRP maximum.  During this range, 
PIAPS levels can significantly elevate PIRP as compared to other PIAPS range where PIRP 
remains relatively low.  β parameter represents a coupling factor of PIRP versus PIAPS levels, 
reflecting how significant or effective PIAPS level affects PIRP.   
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Figure 2.  Scheme of Pathogen Infection Recovery Probability (PIRP) versus certain 
Proinflammatory Anti-Pathogen Species (PIAPS) levels based on equation 1. 
 
 Based on this model, the PIRP-PIAPS curve are divided into two stages:  1) Stage I or the 
PIRP rising stage corresponds to pathogen/APS evolution time period between t0 to te as shown in 
Figure 1:  The PIRP of the pathogen infected host starts to rise as the host normal immune response 
generated APS (including PIAPS) are growing efficiently from initial levels of x0 (x0 can be zero 
for pathogen specific APS) and eventually approaching and maintaining at their equilibrium levels 
xe (blue solid line) where the pathogens are being eliminated or cleared.  2) Stage II or the PIRP 
descending stage:  The PIAPS level further grow beyond their equilibrium levels xe as represented 
by the long dashed blue line (representing immunodysregulation such as hyperinflammatory 
disorders) [2, 4-12, 18-20], the PIRP descends presumably due to excessive PIAPS start to damage 
the normal or healthy tissues or organs.  Eventually the PIRP could descend to a very low level 
due to heavy damages of tissues (particularly lung tissues) that could result in multiple organ 
failures [2, 7-12, 18-20].   
 Based on this model, the general therapeutic strategies for minimizing mortality is to 
achieve and/or to sustain maximum PIRP via a two-stage protocol as following:  1) In the stage I 
or the PIRP rising stage between t0 and te, if the host has a normal immune response to the pathogen 
infection, the host’s APS/PIAPS should grow efficiently toward their equilibrium (or saturation) 
levels xe where the pathogens are being eliminated or cleared.  In this situation and stage, viral 
targeted therapies appear unnecessary except supportive therapies are needed for the following 
situations: a) If the host exhibits breath difficulty (dyspnea) or low blood oxygen level due to the 
liquids/mucous in the lungs (lung infections), then mechanical respiration ventilators and/or 
oxygen therapy may be utilized to prevent potential oxygen deficiency syndromes and related 
complications (hypoxemia and hypoxia); b) If the pathogen growth is out of control (such as in the 
cases of the host’s certain immune deficiency syndromes), than either pathogen 
inhibitors/suppressors (if available) or APS boosters/enhancers (immuno-stimulators, including 
certain WBC therapies, antibody/immunoglobin therapies, interferon therapies, as well as 
therapies utilizing plasma and antibodies obtained from the convalescent patients) may be 
administered to minimize potential viral damage resulted complications, but the immuno-
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stimulations must be administered at the right time (in stage I before te), right type (APS/PIAPS 
boosters/enhancers instead of inhibitors/suppressors), and at the right dosages (i.e., APS/PIAPS 
levels should be carefully monitored and controlled to be equal or close to their equilibrium or 
saturation levels xe).  2) In the stage II or the PIRP descending stage after te, when the PIAPS levels 
are excessive or their growth are out of control (dysregulated), the most critical or essential 
therapeutic task in the post te period or stage II shall be to promptly terminate or suppress the 
further growth of the PIAPS levels (immuno-suppressing, a variety of anti-inflammatory methods 
may be tested) at or nearby their equilibrium levels xe, while pathogen inhibitors/suppressors may 
not be necessary at this time if the pathogens are eliminated.  In case where the coupling of the 
host generated APS to the pathogen is very poor, i.e., hyper-inflammation or cytokine storm has 
occurred and the pathogen level is still high, pathogen suppressors/inhibitors (if available), anti-
inflammatory or non-inflammatory APS, as well as PIAPS suppressors may all be administered at 
this situation and in this stage but with carefully controlled dosages.  Certain host immune system 
generated anti-inflammatory species (AIS, such as IL-10) may grow in order to counter the 
inflammation, but such anti-inflammatory response could be too slow and may eventually reduce 
the host PIAPS levels well below the equilibrium levels and may result the host to 
immunoparalysis [20].  A number of therapeutic PIAPS control (immunomodulation) efforts have 
been reported in recent years [4-12], however, the timing, type, and dosages of PIAPS 
suppressors/antagonists must be carefully monitored and controlled and this appears has not yet 
done, as PIAPS over-suppression or at wrong stage could result in delayed or incomplete pathogen 
elimination as well as vulnerability of host re-infection or secondary infections and related 
complications [20].  Finally, since the host’s mental/psychological status or modes (fear including 
claustrophobia, anxiety, distress, depression, etc.) could trigger host’s catecholamine/adrenaline 
production which in turn could boost APS/PIAPS levels, macrophage-cytokine self-amplifying 
loop MCSAL [11], and inflammations [21], and may result in mode-inflammation self-amplifying 
loop (MISAL), psychological counselling to the host thus also appear very important to improve 
host’s PIRP.  Precise, fast, convenient, and reliable protocols of measuring and monitoring 
pathogen and key “Double-edged sword” PIAPS levels are essential not only to validate this 
model, but to eventually utilize this model and its generated protocols for safe and effective 
therapeutic treatments of the infected hosts.  Both pathogen and key PIAPS should be targeted as 
critical biomarkers ASAP.   
As an example, in the case of COVID-19, while there appears lack of evidences of organ 
damages due to virus [22], excess levels or presences of macrophages, neutrophils, and 
inflammatory cytokines (such as Interleukin-6) were observed in multiple damaged organs in the 
autopsies and biopsies of the SARS-CoV-2 virus infected hosts [18].  Though APS/PIAPS boosters 
(such as interferon INF-alpha, gamma immunoglobulin, convalescent plasma collected from 
recovered patients) were recommended for COVID-19 infection treatments [18], based on this 
model, such treatments may best be used only for those hosts with deficient or very weak immune 
responses and should be administered in stage I.  PIAPS suppression via a series of inflammation 
antagonists, or cytokine elimination via blood purification [18] appear useful for controlling CRS 
but they should be done after te in the stage II, the PIAPS level control are extremely critical.  Most 
importantly, the levels of SARS-coV-2 and key PIAPS levels (particularly IL-6, macrophages, 
neutrophils) at appropriate time intervals need to be measured and monitored precisely and closely 
in order to monitor and determine the virus growth, virus elimination onset time te and the 
corresponding PIAPS equilibrium levels xe.  For COVID-19 infection, it appears many host’s 
antibody lgG equilibrium level xe is about four times of its initial level x0 [18].  An approach on 
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controlling dysregulated interferon INF-I production in COVID-19 infection [19] appears 
potentially useful for validating or utilizing this model, again the interferon INF-I level control 
should be done after te and the level should not be over suppressed well below xe.  Another example 
where this two-stage model might be applicable is the application of certain anti-oxidants 
(assuming Vitamins-C/E have such functions), where the anti-oxidant or radical scavengers appear 
needed only during stage II, this is because pathogen supressing oxidative radicals are actually 
needed in stage I.  Finally, multiple host units may be utilized to obtain average values of all six 
parameters of this model (t0,, x0, te, xe, α, β) for a particular host group, and the average values may 
be useful for therapeutic treatments of an individual host that is same or similar to the members of 
the group.   
In summary, a bell shaped normal distribution function is proposed to model the Pathogen 
Infection Recovery Probability (PIRP) versus Proinflammatory Anti-pathogen Species (PIAPS) 
levels in a microorganism based pathogen infected host.  Based on this model, therapeutic 
strategies should be based on two stages: In the first stage, treatments may not be necessary for 
most hosts with normal immune responses as PIRPs are expected to grow and remain at the 
maximum due to APS/PIAPS growing to and remaining at the equilibrium levels xe for certain 
periods, except supportive treatments are needed for oxygen deficiency syndromes.  Hosts with 
weak or deficient anti-pathogen immune responses may need either pathogen suppressors or 
immuno-stimulators, however, timing, type, and dosages of both pathogen suppressors and 
immuno-stimulators are critical. In the second or the PIRP descending stage II due to PIAPS 
excessive or abnormal growth or levels, it is essential to control the PIAPS around their equilibrium 
levels xe via immuno-suppressors or inflammation antagonists.  If pathogen levels are still high in 
stage II, then anti-inflammatory or non-inflammatory immuno-stimulators are desired.  Again, 
timing, types, and dosages of therapeutic treatments are extremely critical depending on the PIRP 
stages and on pathogen/PIAPS levels.  Precise and timely monitoring and controls of both 
pathogen and PIAPS levels are essential in order to fully characterize and utilize this model.  
Increased survivability or reduced mortality could be potential outcome if this or related models 
are fully developed, well characterized, and implemented after carefully designed and controlled 
clinical trials.  For instance, for current COVID-19 infections, immunomodulation via timely and 
precise monitoring and level controls of key biomarkers (including the virus, IL-6, macrophages 
and/or neutrophils, oxidative radical species, IL-10, etc) appear essential to reduce the mortality.   
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